Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma

References

• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in MM: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128.
   PubMed Web of Science ®Google Scholar
• Kistler KD, Kalman J, Sahni G, et al. Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: an observational, retrospective, cohort study. Clin Lymphoma Myeloma Leuk. 2017;17(2):89 .e3–96.e3.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Milan A, Ferri C, et al. Cardiovascular adverse events in modern myeloma therapy – incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica. 2018;103(9):1422–1432.
   PubMed Web of Science ®Google Scholar
• Chen JH, Lenihan DJ, Phillips SE, et al. Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma. Cardiooncology. 2017;3:4.
   PubMedGoogle Scholar
• Cornell RF, Ky B, Weiss BM, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol. 2019;37(22):1946–1955.
   PubMed Web of Science ®Google Scholar
• Wu P, Oren O, Gertz MA, et al. Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management. Curr Oncol Rep. 2020;22(7):66.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112(9):3582–3586.
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281–3290.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327–1337.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(8):728–734.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Quach H, Mateos M, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186–197.
   PubMed Web of Science ®Google Scholar
• Chari A, Stewart AK, Russell SD, et al. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Adv. 2018;2(13):1633–1644.
   PubMed Web of Science ®Google Scholar
• Lendvai N, Tsakos I, Devlin SM, et al. Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leuk Lymphoma. 2018;59(8):1981–1985.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Milan A, D'Agostino M, et al. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib a consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. J Intern Med. 2019;286(1):63–74.
   PubMed Web of Science ®Google Scholar
• Kawaji-Kanayama Y, Kobayashi T, Muramatsu A, et al. Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: the Kyoto clinical hematology study group, multicenter, pilot, prospective, observational study in Asian patients. Cancer Rep. 2021;14:e1476.
   Google Scholar
• van Kimmenade RR, Januzzi JL Jr. Emerging biomarkers in heart failure. Clin Chem. 2012;58(1):127–138.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355(25):2631–2639.
   PubMed Web of Science ®Google Scholar
• Salomaa V, Wu KK. Soluble thrombomodulin as predictor of incident coronary heart disease. Lancet. 1999;354(9190):1646–1647.
   PubMed Web of Science ®Google Scholar
• Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical prediction modelling. Fam Med Community Health. 2020;8(1):e00026216.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Dold SM, Ihorst G, et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016;101(9):1110–1119.
   PubMed Web of Science ®Google Scholar
• Waxman AJ, Clasen S, Hwang WT, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018;4(3):e174519.
   PubMed Web of Science ®Google Scholar
• Meissner A. Hypertension and the brain: a risk factor for more than heart disease. Cerebrovasc Dis. 2016;42(3-4):255–262.
   PubMed Web of Science ®Google Scholar
• Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557–1562.
   PubMed Web of Science ®Google Scholar
• McLenachan JM, Henderson E, Morris KI, et al. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med. 1987;317(13):787–792.
   PubMed Web of Science ®Google Scholar
• Shah C, Bishnoi R, Jain A, et al. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Leuk Lymphoma. 2018;59(11):2557–2569.
   PubMed Web of Science ®Google Scholar
• Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–2247.
   PubMed Web of Science ®Google Scholar
• Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953–964.
   PubMed Web of Science ®Google Scholar
• Fradley MG, Groarke JD, Laubach J, et al. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. Br J Haematol. 2018;180(2):271–275.
   PubMed Web of Science ®Google Scholar
• Atrash S, Tullos A, Panozzo S, et al. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J. 2015;5(1):e272.
   PubMedGoogle Scholar
• Abe Y, Kobayashi T, Narita K, et al. Left ventricular diastolic function as a possible predictor of severe carfilzomib-induced cardiovascular events. Blood Adv. 2019;3(11):1725–1728.
   PubMed Web of Science ®Google Scholar
• Chamarthi B, Williams GH, Ricchiuti V, et al. Inflammation and hypertension: the interplay of interleukin-6, dietary sodium, and the renin-angiotensin system in humans. Am J Hypertens. 2011;24(10):1143–1148.
   PubMed Web of Science ®Google Scholar
• Chae CU, Lee RT, Rifai N, et al. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001;38(3):399–403.
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998;31(2):391–398.
   PubMed Web of Science ®Google Scholar
• Bautista LE, Vera LM, Arenas IA, et al. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19(2):149–154.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420.
   PubMed Web of Science ®Google Scholar